Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Trial of Nivolumab Plus Ipilimumab in Patients With Renal Medullary Carcinoma

NCT03274258 is registered in ClinicalTrials.gov with M.D. Anderson Cancer Center as lead sponsor.

NCT NCT03274258
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03274258 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Trial of Nivolumab Plus Ipilimumab in Patients With Renal Medullary Carcinoma
Lead sponsor
M.D. Anderson Cancer Center
Phase
Phase 2
Overall status
Terminated
Start date
May 29, 2018
Completion date
November 21, 2025
Enrollment
10 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

kidney medullary carcinoma, loss of ini 1 protein expression, stage iii renal cell cancer ajcc v8, stage iv renal cell cancer ajcc v8